Journal Article Summary
The article examines the challenges clinicians face when using telehealth to manage drug-induced movement disorders (DIMDs), particularly tardive dyskinesia (TD), during the COVID-19 pandemic. This topic is significant because TD can severely affect patients' quality of life, and regular monitoring is essential for timely diagnosis and treatment. The shift to telehealth was intended to maintain patient care during the pandemic, but it has raised concerns about the effectiveness of remote evaluations compared to in-person visits.
The study involved an online survey of 277 clinicians from psychiatry and neurology who had prescribed treatments for DIMDs. The findings revealed that telehealth visits, especially phone consultations, made it difficult for clinicians to observe key symptoms and signs necessary for diagnosing DIMDs. Clinicians reported that patients without caregivers and those with lower functioning were particularly at risk for missed diagnoses. Additionally, socioeconomic barriers, such as limited access to technology, further complicated the ability to provide adequate care through telehealth.
Despite the insights gained, the study has limitations, including a focus on clinicians who already used telehealth, which may not represent the broader challenges faced by all providers. Patients and caregivers should discuss these challenges with healthcare professionals, particularly regarding the importance of regular evaluations for DIMDs and the potential need for in-person visits. Understanding the limitations of telehealth can help patients advocate for their care and ensure they receive appropriate monitoring and treatment for their conditions.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Bera Rimal, Bron Morgan, Benning Betsy, Cicero Samantha, Calara Heintje, Darling Diane, Franey Ericha, Martello Kendra, et al.. Clinician Perceptions of the Negative Impact of Telehealth Services in the Management of Drug-Induced Movement Disorders and Opportunities for Quality Improvement: A 2021 Internet-Based Survey. Neuropsychiatric Disease and Treatment 2022. DOI: 10.2147/NDT.S385960. PMID: 36570023. PMCID: PMC9784394.
Featured Pill Pals Product
Benztropine 0.5 mg Tablets --- Generic For Cogentin --- Leading Pharma
Benztropine 0.5 mg Tablets — Generic For Cogentin — Leading Pharma is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. Prescription required.
Request a prescription transfer and our pharmacy team will help coordinate the next step.
